QLF 31907
Alternative Names: QLF-31907Latest Information Update: 09 Jul 2024
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Malignant melanoma; Urogenital cancer
Most Recent Events
- 31 May 2024 Efficacy and safety data from the Phase Ia trial in Cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology 2024 (ASCO-2024)
- 01 May 2024 Qilu Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage disease, Combination therapy) in unknown location (IV) (NCT06394713)
- 26 Apr 2023 Qilu Pharmaceuticals plans a phase II trial for Malignant melanoma and Urogenital cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China (NCT05823246)